Mylan Pharmaceuticals and Banner Pharmacaps, a wholly-owned subsidiary of Patheon, have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic version of Targretin, which is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Their pending litigation will b...